Kairos Pharma CEO John Yu stated, “The initiation of this trial speaks to the dedication of the Kairos team to execute on its goals to develop therap...
As part of the agreement, Armatus will leverage Andelyn’s extensive experience in adeno-associated virus (AAV) production and its proprietary suspens...
Menarini Silicon Biosystems, a pioneer of liquid biopsy and single-cell technologies, announced the recent publication of the STIC CTC trial data demonstra...
MoBiTec will be integrated with BIOZOL Diagnostica GmbH, a subsidiary of Calibre Scientific, enhancing its sales capabilities and product range for custome...
Neuralace Medical, Inc., an innovator in pain management technology, proudly announces the FDA clearance of its groundbreaking product, Axon Therapy ...
Base4 Biotechnology (formerly known as Nymirum) announced that it has expanded its license agreement with Servier to strengthen the companies' strategic co...
Omniose, a preclinical stage biotechnology company, today announced an exclusive collaboration agreement with AstraZeneca for the search for potential vacc...
Novartis to acquire SanReno's product pipeline and capabilities, including the exclusive rights for Greater Chinaand Singapore Transaction reflects the&...
Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) product...
QIAGEN to open regional headquarters in Riyadh, Saudi Arabia, at the beginning of 2024 to support growing presence in the region QIAGEN signed Memor...
-Sail Biomedicines, Inc. (“Sail” or the “Company”), a Flagship Pioneering company and leader in RNA-based programmable medicines, a...
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company ded...
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development...
SNK01 consists of a non-genetically modified NK cell product with enhanced cytotoxicity and activating receptor expression for the treatment of moderate AD...
© 2025 Biopharma Boardroom. All Rights Reserved.
